Brian D Adams

List of Publications by Year
in descending order

25 papers	2,604 citations	448610 19 h-index	685536 24 g-index
27 all docs	27 docs citations	27 times ranked	5431 citing authors

#	Article	IF	Citations
1	A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. IScience, 2020, 23, 100878.	1.9	13
2	Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor. Rna, 2019, 25, 352-363.	1.6	15
3	Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Research and Treatment, 2018, 170, 55-67.	1.1	25
4	linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer. Transcription, 2018, 9, 17-29.	1.7	22
5	The role of long noncoding RNAs in cancer metastasis. Journal of Cancer Metastasis and Treatment, 2018, 4, 19.	0.5	10
6	cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene, 2017, 36, 512-524.	2.6	20
7	Androgen receptor and miR-206 regulation in prostate cancer. Transcription, 2017, 8, 313-327.	1.7	15
8	The regulatory role of miRNAs on VDR in breast cancer. Transcription, 2017, 8, 232-241.	1.7	22
9	Prdm1 Regulates Thymic Epithelial Function To Prevent Autoimmunity. Journal of Immunology, 2017, 199, 1250-1260.	0.4	53
10	Targeting noncoding RNAs in disease. Journal of Clinical Investigation, 2017, 127, 761-771.	3.9	527
11	The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nature Immunology, 2016, 17, 433-440.	7.0	123
12	The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opinion on Therapeutic Targets, 2016, 20, 737-753.	1.5	82
13	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 927-939.	0.4	128
14	Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancer. , 2015, , .		1
15	Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer. , 2015, , .		0
16	Aberrant Regulation and Function of MicroRNAs in Cancer. Current Biology, 2014, 24, R762-R776.	1.8	408
17	Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. Journal of Allergy and Clinical Immunology, 2013, 132, 170-181.e9.	1.5	187
18	An InÂVivo Functional Screen Uncovers miR-150-Mediated Regulation of Hematopoietic Injury Response. Cell Reports, 2012, 2, 1048-1060.	2.9	42

#	Article	IF	Citations
19	ERÎ±, microRNAs, and the epithelialâ€“mesenchymal transition in breast cancer. Trends in Endocrinology and Metabolism, 2012, 23, 73-82.	3.1	103
20	Argonaute-2 Expression Is Regulated by Epidermal Growth Factor Receptor and Mitogen-Activated Protein Kinase Signaling and Correlates with a Transformed Phenotype in Breast Cancer Cells. Endocrinology, 2009, 150, 14-23.	1.4	136
21	The Role of miR-206 in the Epidermal Growth Factor (EGF) Induced Repression of Estrogen Receptor-Î± (ERÎ±) Signaling and a Luminal Phenotype in MCF-7 Breast Cancer Cells. Molecular Endocrinology, 2009, 23, 1215-1230.	3.7	98
22	Involvement of MicroRNAs in Breast Cancer. Seminars in Reproductive Medicine, 2008, 26, 522-536.	0.5	44
23	The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-Î± (ERÎ±) and Represses ERÎ± Messenger RNA and Protein Expression in Breast Cancer Cell Lines. Molecular Endocrinology, 2007, 21, 1132-1147.	3.7	456
24	Stratum-Specific Expression of Human Transferrin Receptor Increases Iron in Mouse Epidermis. Journal of Investigative Dermatology, 2006, 126, 648-652.	0.3	9
25	Iron in Skin of Mice with Three Etiologies of Systemic Iron Overload. Journal of Investigative Dermatology, 2005, 125, 1200-1205.	0.3	19